Close Menu

NEW YORK (GenomeWeb) – Definiens announced today that Takeda Pharmaceuticals will use its new cloud-based digital pathology platform in its translational and biomarker research.

When combined with deeply researched biomarker analysis, Definiens said its new platform, VeriTrova, can help translate biomarker research into the clinic through a new generation of diagnostics. Takeda, an early adopter of the platform, plans to use it for comprehensive tissue-based analysis in its clinical trials, and to support its clinical biomarker development programs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.